The company said net sales for Q4 2023 rose to $732.0 million, up 3.3%, and full-year net sales rose to $2.950 billion, up 2.2%. Organic net sales growth was 1.4% for Q4 and 1.6% for the full year.

1. 01

   The company said net sales for Q4 2023 rose to $732.0 million, up 3.3%, and full-year net sales rose to $2.950 billion, up 2.2%. Organic net sales growth was 1.4% for Q4 and 1.6% for the full year.

2. 02

   The company said full-year 2023 reported-diluted EPS rose 1.9% to $7.88, while adjusted-diluted EPS fell 5.8% to $8.08. Reported-diluted EPS for Q4 rose 34.6% to $1.83.

3. 03

   West Pharmaceutical said full-year 2023 operating cash flow rose 7.3% to $776.5 million. It said capital expenditures were $362.0 million (compared with $284.6 million in 2022), and free cash flow fell 5.7% to $414.5 million.

4. 04

   The company gave full-year 2024 guidance for net sales of $3.000 billion to $3.025 billion and adjusted-diluted EPS of $7.50 to $7.75. It said it expects organic net sales growth of approximately 2% to 3% and capital expenditures of $350 million.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.